Skin events (SE) among 1,126 patients (Pts) treated with lapatinib (L), an oral dual ErbB1/2 tyrosine kinase inhibitor (TKI)
Year: 2007
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: R. Sweetman, M. E. Lacouture, M. Koehler, S. Laabs, A. Preston, K. L. Blackwell
Institution: Duke Medical Center
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2274157074